A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

BACKGROUND: Programmed cell death protein 1 (PD-1) is a key immune checkpoint that regulates peripheral tolerance and protects against autoimmunity. Programmed death ligand-2 (PD-L2) is a less studied ligand to PD-1 and has yet to be fully explored, especially in pancreatic ductal adenocarcinoma (PD...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Zhang, Yiyin, Xu, Jin, Hua, Jie, Liu, Jiang, Liang, Chen, Meng, Qingcai, Wei, Miaoyan, Zhang, Bo, Yu, Xianjun, Shi, Si
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716876/
https://ncbi.nlm.nih.gov/pubmed/31464648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0703-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia